PL-5283 Inhibitors
PL-5283 inhibitors pertain to a specific class of chemical compounds that interact with targeted molecular pathways, exhibiting a high degree of selectivity and specificity. The designation 'PL-5283' typically refers to a unique identifier within a chemical series, hinting at a structured approach to compound development and classification. These inhibitors are characterized by their ability to modulate biochemical processes through binding interactions, often with proteins or enzymes that play crucial roles within cellular mechanisms. The nature of these interactions involves the steric and electronic complementarity between the inhibitor and its target, which can result in the alteration of the target's activity. The chemical structure of PL-5283 inhibitors is usually complex, featuring a core scaffold that anchors key functional groups, enabling the precise interaction with the active or allosteric sites of their targets.
From a synthetic chemistry perspective, the creation of PL-5283 inhibitors often involves multi-step organic synthesis, using principles of medicinal chemistry to optimize the interaction with the biological target. The optimization process may include the modification of substituents to improve binding affinity, increase chemical stability, or enhance selectivity, ensuring minimal off-target effects. The physicochemical properties of these inhibitors, such as solubility, permeability, and metabolic stability, are fine-tuned to achieve the desired profile. The specificity of PL-5283 inhibitors is also a result of the rigorous structure-activity relationship (SAR) studies that guide their development. Through these methods, the three-dimensional structure of PL-5283 inhibitors is elucidated, allowing for a deeper understanding of their interaction at the molecular level.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). PL-5283, if it is a downstream target of the PI3K/Akt pathway, would experience reduced phosphorylation and subsequent inactivation due to the inhibition of PI3K by Wortmannin. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another inhibitor of PI3K, which could lead to decreased activation of the downstream Akt pathway. Inhibition of this pathway would result in decreased activity of PL-5283 if it is regulated by Akt-mediated signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR) pathway, which is a downstream effector of PI3K/Akt signaling. If PL-5283 is a protein synthesized in response to mTOR activation, Rapamycin would indirectly decrease its function by inhibiting mTOR. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which acts upstream of extracellular signal-regulated kinases (ERK1/2). Inhibition of MEK could lead to decreased ERK1/2-mediated activation of PL-5283 if it is part of the MAPK/ERK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2. Like PD98059, it would prevent the activation of ERK1/2 and subsequent activation of PL-5283 if it is dependent on the MAPK/ERK signaling pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. If PL-5283's activity is modulated by p38 MAPK-dependent phosphorylation, this compound would lead to its functional inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which can regulate various cellular processes. If PL-5283 is a substrate of JNK or is regulated by JNK signaling, SP600125 would indirectly inhibit its function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can prevent the degradation of IκB, thus inhibiting the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway. If PL-5283 is regulated by NF-κB, Bortezomib would lead to its decreased activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. If Src kinases are involved in the activation of PL-5283, Dasatinib would result in its decreased functional activity through inhibition of these upstream kinases. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib inhibits certain tyrosine kinases, including Abl, PDGFR, and c-Kit. If PL-5283 is activated by one of these kinases or their downstream signaling, Imatinib would lead to its functional inhibition. | ||||||